JPET

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


Journal of Pharmacology And Experimental Therapeutics Fast Forward
First published on August 4, 2006; DOI: 10.1124/jpet.106.102236


0022-3565/06/3192-595-603$20.00
JPET 319:595-603, 2006
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
jpet.106.102236v1
jpet.106.102236v2
jpet.106.102236v3
319/2/595    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Yang, S.
Right arrow Articles by Block, M. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Yang, S.
Right arrow Articles by Block, M. L.

NEUROPHARMACOLOGY

Pituitary Adenylate Cyclase-Activating Polypeptide (PACAP) 38 and PACAP4–6 Are Neuroprotective through Inhibition of NADPH Oxidase: Potent Regulators of Microglia-Mediated Oxidative Stress

Sufen Yang, Jun Yang, Zhengqin Yang, Posee Chen, Alison Fraser, Wei Zhang, Hao Pang, Xi Gao, Belinda Wilson, Jau-Shyong Hong, and Michelle L. Block

Laboratory of Pharmacology and Chemistry, National Institute of Environmental Health Sciences, National Institutes of Health, Research Triangle Park, North Carolina (S.Y., J.Y., Z.Y., A.F., W.Z., H.P., X.G., B.W., J.-S.H., M.L.B.); and Institute of Basic Medical Sciences and Department of Psychiatry, College of Medicine, National Cheng Kung University, Tainan, Taiwan (P.C.)

Microglial activation is implicated in the progressive nature of numerous neurodegenerative diseases, including Parkinson's disease. Using primary rat mesencephalic neuron-glia cultures, we found that pituitary adenylate cyclase-activating polypeptide (PACAP) 38, PACAP27, and its internal peptide, Gly-Ile-Phe (GIF; PACAP4–6), are neuroprotective at 10–13 M against lipopolysaccharide (LPS)-induced dopaminergic (DA) neurotoxicity, as determined by [3H]DA uptake and the number of tyrosine hydroxylase-immunoreactive neurons. PACAP38 and GIF also protected against 1-methyl-4-phenylpyridinium+-induced neurotoxicity but only in cultures containing microglia. PACAP38 and GIF ameliorated the production of microglia-derived reactive oxygen species (ROS), where both LPS- and phorbol 12-myristate 13-acetate-induced superoxide and intracellular ROS were inhibited. The critical role of NADPH oxidase for GIF and PACAP38 neuroprotection against LPS-induced DA neurotoxicity was demonstrated using neuron-glia cultures from mice deficient in NADPH oxidase (PHOX–/–), where PACAP38 and GIF reduced tumor necrosis factor {alpha} production and were neuroprotective only in PHOX+/+ cultures and not in PHOX–/– cultures. Pretreatment with PACAP6–38 (3 µM; PACAP-specific receptor antagonist) was unable to attenuate PACAP38, PACAP27, or GIF (10–13 M) neuroprotection. PACAP38 and GIF (10–13 M) failed to induce cAMP in neuronglia cultures, supporting that the neuroprotective effect was independent of traditional high-affinity PACAP receptors. Pharmacophore analysis revealed that GIF shares common chemical properties (hydrogen bond acceptor, positive ionizable, and hydrophobic regions) with other subpicomolar-acting compounds known to inhibit NADPH oxidase: naloxone, dextromethorphan, and Gly-Gly-Phe. These results indicate a common high-affinity site of action across numerous diverse peptides and compounds, revealing a basic neuropeptide regulatory mechanism that inhibits microglia-derived oxidative stress and promotes neuron survival.


Received for publication February 6, 2006
Accepted August 3, 2006.

Address correspondence to: Dr. Michelle L. Block, Laboratory of Pharmacology and Chemistry, National Institute of Environmental Health Sciences, National Institutes of Health, MD F1-01, P.O. Box 12233, Research Triangle Park, NC 27709. E-mail: block{at}niehs.nih.gov




This article has been cited by other articles:


Home page
Pharmacol. Rev.Home page
D. Vaudry, A. Falluel-Morel, S. Bourgault, M. Basille, D. Burel, O. Wurtz, A. Fournier, B. K. C. Chow, H. Hashimoto, L. Galas, et al.
Pituitary Adenylate Cyclase-Activating Polypeptide and Its Receptors: 20 Years after the Discovery
Pharmacol. Rev., September 1, 2009; 61(3): 283 - 357.
[Abstract] [Full Text] [PDF]


Home page
Toxicol SciHome page
Z. Yang, S. Yang, S. Y. Qian, J.-S. Hong, M. B. Kadiiska, R. W. Tennant, M. P. Waalkes, and J. Liu
Cadmium-Induced Toxicity in Rat Primary Mid-brain Neuroglia Cultures: Role of Oxidative Stress from Microglia
Toxicol. Sci., August 1, 2007; 98(2): 488 - 494.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2006 by the American Society for Pharmacology and Experimental Therapeutics.